WJA
PVLA

Williams Jones & Associates’s Palvella Therapeutics PVLA Stock Holding History

Williams Jones & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-175
Closed -$71K – 465
2018
Q2 		$71K Hold
175
– – ﹤0.01% 430
2018
Q1 		$95K Sell
175
-125
-42% -$77.4K ﹤0.01% 428
2017
Q4 		$181K Hold
300
– – ﹤0.01% 411
2017
Q3 		$138K Buy
+300
New +$128K ﹤0.01% 414

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Williams Jones & Associates's PVLA Position: Q3 2018 in Review

Williams Jones & Associates sold out of Palvella Therapeutics (PVLA) in Q3 2018, closing a stake of 175 shares — an estimated $71K sold.

Williams Jones & Associates first reported a position in PVLA in Q3 2017 and held it in 4 quarters. The position peaked at $181K in Q4 2017. 105 funds tracked by Wall St. Rank hold PVLA as of Q3 2018.

  • Williams Jones & Associates reported no remaining Palvella Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Williams Jones & Associates sold 175 Palvella Therapeutics shares in Q3 2018, an estimated $71K.
  • Williams Jones & Associates first reported a position in Palvella Therapeutics in Q3 2017 and held it in 4 quarters.
  • Williams Jones & Associates's Palvella Therapeutics position peaked at $181K in Q4 2017.
  • 105 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2018.

Based on Williams Jones & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.